QRG Capital Management Inc. Sells 16,527 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

QRG Capital Management Inc. decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 79.8% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,184 shares of the biopharmaceutical company's stock after selling 16,527 shares during the quarter. QRG Capital Management Inc.'s holdings in Regeneron Pharmaceuticals were worth $2,654,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $25,000. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares in the last quarter. Tompkins Financial Corp acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $32,000. Finally, Curat Global LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. Institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. UBS Group decreased their price objective on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research report on Thursday, June 5th. Royal Bank Of Canada lowered Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price target on the stock. in a research note on Friday, May 30th. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Wall Street Zen cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Finally, Robert W. Baird cut their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $836.48.

Regeneron Pharmaceuticals Stock Up 0.9%

Shares of REGN traded up $4.72 during midday trading on Thursday, hitting $513.58. The stock had a trading volume of 841,026 shares, compared to its average volume of 884,759. The firm has a market cap of $55.45 billion, a price-to-earnings ratio of 13.07, a price-to-earnings-growth ratio of 1.86 and a beta of 0.31. The company has a 50 day simple moving average of $559.88 and a two-hundred day simple moving average of $645.05. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the prior year, the business posted $9.55 EPS. The firm's quarterly revenue was down 3.7% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.